Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin, Irinotecan and ZD 1839 in Esophageal or Gastric Carcinomas
NCT00215995Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2003
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in esophageal carcinoma and gastric cancer (GC), sponsored by Moffitt Cancer Center. Primary endpoint: Objective Response Rate at 48 months. Started Jul 2003; status: completed.
02
Drugs
03
Conditions
esophageal carcinomagastric cancer (GC)
Beyond the preview
Go deeper on NCT00215995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215995.